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Abstract
Background: Hematologic malignancies arising in the setting of established germ cell tumors have been previously
described and have a dismal prognosis. Identification of targetable mutations and pathway dysregulation through
massively parallel sequencing and functional assays provides new approaches to disease management.
Case Presentation: Herein, we report the case of a 23-year-old male who was diagnosed with a mediastinal germ cell
tumor and subsequent acute myeloid leukemia. A shared clonal origin was demonstrated through identification of
identical NRAS and TP53 somatic mutations in both malignancies. The patient’s leukemia was refractory to standard
therapies with short interval relapse. Functional assays demonstrated the patient’s blasts to be sensitive to the
mitogen-activated protein kinase kinase (MEK) inhibitor trametinib, correlating with the activating NRAS mutation. The
patient experienced a sustained partial remission while on trametinib therapy but ultimately suffered relapse of the
germ cell tumor. The leukemic clone remained stable and sensitive to trametinib at that time.
Conclusions: This case highlights the potential power of combining genetic sequencing and in vitro functional assays
with targeted therapies in the treatment of rare diseases.
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Background
Mediastinal germ cell tumors (GCT) are capable of malig-
nant transformation into tumors of endodermal, mesoder-
mal, and ectodermal origin. With regard to hematologic
malignancies, GCTare most frequently associated with acute
myeloid leukemia (often with megakaryoblastic differenti-
ation); but myelodysplastic syndromes, malignant histiocyto-
sis, myeloproliferative neoplasms, and acute lymphoblastic
leukemia have all been described [1–7]. Identification of
shared cytogenetic abnormalities in the GCTand hematologic
malignancy (most commonly isochromosome 12p) indicate a
clonal relationship and common precursor [8].
The prognosis for GCT with a concurrent hematologic
malignancy is poor, as the disease is usually refractory to
conventional chemotherapy and patients are unable to at-
tain a clinical remission [9]. For those that do attain a re-
mission, relapse without consolidative allogeneic stem cell
transplant is inevitable, and successful outcomes are lim-
ited to two cases in which patients underwent allogeneic
hematopoietic stem cell transplant early in the first
complete remission [1, 10]. Given these dismal outcomes,
novel therapeutic approaches are needed.
Here, we report the case of a young man with metasyn-
chronous presentation of a GCT and acute myeloid
leukemia (AML). Following failure of conventional cytotoxic
chemotherapy, a functional in vitro assay was used to iden-
tify a targeted therapeutic agent with activity against the
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leukemic blasts: trametinib, an inhibitor of mitogen-activated
protein kinase kinase (MEK). This in vitro sensitivity corre-
lated with the identification of a somatic NRAS missense
mutation, which also predicts sensitivity to MEK inhibition.
The patient was treated with trametinib for 6 months, during
which time his leukemia remained stable. This case high-
lights the utility of combining mutational profiling with func-
tional in vitro testing of the leukemic clone to identify
effective personalized therapies for rare malignancies.
Case presentation
A 23-year-old male presented with fevers, hemoptysis, and
an 18-cm anterior mediastinal mass (Fig. 1a). A computed
tomography-guided core biopsy of the mass contained
mostly necrotic tissue with rare atypical cells that were
partially positive for alpha-fetoprotein (AFP), glypican, and
pancytokeratin by immunohistochemistry. Serum AFP was
elevated at >60,000 ng/mL, leading to a presumptive diag-
nosis of a mediastinal germ cell tumor. The patient was
treated with four cycles of VIP (vinblastine, ifosfamide,
etoposide) with concomitant decrease in serum AFP to
300 ng/mL. Prior to resection of the residual mediastinal
mass (4 months after the original diagnosis), a complete
blood count (CBC) demonstrated elevation of the WBC to
55 k/μL with 28 % circulating myeloid blasts. His lactate
dehydrogenase (LDH) was markedly elevated at 17,481 U/
L, although his AFP decreased to 211 ng/mL. A bone mar-
row biopsy demonstrated acute erythroid leukemia with
70–80 % markedly left-shifted erythroid precursors with
dysplastic and megaloblastoid changes and myeloid blasts
accounting for more than 20 % of non-erythroid cell popu-
lation (Fig. 1b). Cytogenetics showed a complex clone
(Fig. 2d). Targeted massively parallel sequencing analysis
also identified TP53 p.G245S and NRAS p.G12C point
mutations at 87 and 86 % allele frequency, respectively (see
Additional file 1 and Additional file 2: Table S1 for details).
As the patient’s mediastinal mass had not yet been resected,
a regimen that would treat both his AML and his residual
germ cell tumor (containing platinum-based therapy)
was desired. For this reason, he was treated with HAEP
(high-dose cytarabine, etoposide, and cisplatin), previ-
ously reported as an effective salvage therapy for AML
[11]. Following induction, the patient achieved morpho-
logic complete remission (CR) of his AML; however,
low-level residual disease was identified by cytogenetics






Fig. 1 A 23-year-old male with a metasynchronous mediastinal germ cell tumor and acute myeloid leukemia. a Computed tomography demonstrated an
18-cm anterior mediastinal mass. b Bone marrow aspirate smear examination (4 months after germ cell tumor diagnosis) demonstrated acute erythroid
leukemia 70–80 % markedly dysplastic and left-shifted erythroid precursors with myeloid blasts (inset) accounting for more than 20 % of non-erythroid
cellularity. c Post-treatment resection of the mediastinal germ cell tumor demonstrated predominantly mature teratoma with focus of rhabdomyosarcoma
(pictured) with desmin positivity (inset). d Separate focus of angiosarcoma was also identified in the mediastinal germ cell tumor (pictured), supported by
CD31 positivity (inset)
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Fig. 2 (See legend on next page.)
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massively parallel sequencing analysis (1 % TP53 and
2 % NRAS mutant allele frequencies).
He was treated with a single cycle of HAEP consolida-
tion therapy, after which he underwent resection of the
mediastinal mass. Histopathologic examination demon-
strated mature teratoma with foci of rhabdomyosarcoma
and angiosarcoma (Fig. 1c, d). Targeted Sanger-based
DNA sequencing analysis identified the same TP53 and
NRAS point mutations present in the acute erythroid
leukemia, confirming a shared clonal origin.
Six weeks after resection of the mediastinal mass, a re-
staging bone marrow biopsy demonstrated relapsed disease
with a morphologically abnormal erythroid series, 5–10 %
myeloid blasts, and persistent TP53 and NRAS mutations at
87 and 86 % allele frequency (Fig. 2e). Cytogenetics identified
the original abnormal clone and the emergence of two add-
itional clones (Fig. 2d). Since the patient was not fit for re-
induction chemotherapy due to recent surgery, his leukemic
cells were isolated and tested against a panel of small mol-
ecule kinase inhibitors to identify in vitro drug sensitivity.
Trametinib was identified as one of the most potent in vitro
inhibitors of leukemic cell viability (Fig. 2a). In vitro small
inhibitory RNA (siRNA) studies further identified that si-
lencing of NRAS had a profound inhibitory effect on blast
viability (Fig. 2b), consistent with his known activating
NRAS mutation (for full list of silenced genes please see
Additional file 3: Table S2). The patient began treatment
with single-agent trametinib therapy obtained on a com-
passionate use basis and had an immediate reduction in
his peripheral blasts after a week of therapy (Fig. 2c).
A bone marrow biopsy after 1 month of trametinib re-
vealed a slight reduction in the blast count (4–5 %) but per-
sistent erythroid dysplasia. Although the AML remained
stable, multiple cytogenetically complex clones were identi-
fied and the TP53 and NRAS mutant allele frequency in-
creased to 96 and 97 %, respectively (Fig. 2e). After 3 months
of trametinib monotherapy, the patient developed pneumo-
nia and Staphylococcus aureus bacteremia. A bone marrow
biopsy at that time demonstrated 8 % blasts and erythroid
dysplasia. Trametinib was held twice due to infections, and
during these intervals, there was an increase in peripheral
blasts, which resolved following resumption of trametinib
(Fig. 2c). A bone marrow biopsy after 5 months of trametinib
therapy demonstrated stability of his AML with 6 % blasts
and erythroid dysplasia. Karyotyping and repeat sequencing
analysis demonstrated continued clonal evolution, with mul-
tiple cytogenetically complex subclones (Fig. 2d). There was
a persistent high-level NRAS and TP53 mutant allele fre-
quency but two additional WT1 point mutations were also
identified at allele frequencies of 20 and 15 %, further indi-
cating clonal evolution (Fig. 2e). Repeat testing confirmed
that the leukemic clone remained sensitive to trametinib in
vitro (data not shown). However, imaging studies performed
in preparation for allogeneic stem cell transplantation dem-
onstrated a 3-cm pulmonary nodule and serum AFP also
rose to 12 ng/dL, consistent with relapse of metastatic
GCT. Given his poor prognosis, the patient opted for
palliative care and died a month later with frank re-
lapse of his AML after trametinib discontinuation.
Discussion
Although exceedingly rare, at least 60 cases of concurrent
mediastinal GCT and hematologic malignancy have been
reported in the literature. A common clonal origin was
long suspected given the temporal relationship between
the two malignancies, and recent work has convincingly
demonstrated conserved isochromosome 12p rearrange-
ments as well as somatic point mutations [12]. We pro-
vide further evidence of the clonal relationship between
GCT and acute erythroid leukemia based on shared NRAS
and TP53 mutations. Furthermore, we demonstrate that
targeted sequencing in combination with functional
screening can identify active drugs for these rare diseases.
Massively parallel sequencing has identified a number of
recurrent mutations in AML. However, the heterogeneity
of mutations [13] precludes a uniform approach to treat-
ment. Furthermore, the functional relevance of identified
mutations is not always known for each AML patient. In
light of this, our group has developed a tripartite approach
to identifying therapeutic targets through (1) small mol-
ecule inhibitor screens, (2) siRNA knock-down, and (3)
targeted massively parallel sequencing. In the presented
case, an activating NRAS mutation and a TP53 mutation
were identified by sequencing. Parallel siRNA and small
molecule screens demonstrated the functional importance
of the activated NRAS/Raf/MEK/ERK pathway in vitro.
MEK inhibitors such as trametinib have shown activity in
RAS-mutated AML; however, the overall response rate is
only 28 %, indicating that a RAS mutation by itself is not
sufficient to predict which patients will respond to therapy
(See figure on previous page.)
Fig. 2 Trametinib inhibits leukemic blast viability in vitro and in vivo and also during cytogenetic and molecular clonal evolution. a Trametinib
inhibits leukemic blast viability in vitro in a dose-dependent manner. b siRNA-mediated knock-down of NRAS decreases in vitro blast viability
(horizontal red bar = 95 % percentile. c Trametinib therapy correlates with partial remission of leukemic blasts. Blast counts (black line) decreased
when on trametinib therapy (red shaded boxes) following AML relapse after standard induction therapy. Note the non-linear time scale. d Karyotyping
demonstrates clonal evolution before and during trametinib therapy. e Targeted massively parallel sequencing demonstrates persistent NRAS and TP53
missense point mutations before and during trametinib therapy; WT1 mutations were identified at the time of germ cell tumor relapse. Identical NRAS
and TP53 mutations were identified by targeted sequencing analysis of the patient’s mediastinal germ cell tumor
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[14]. While trametinib monotherapy did not lead to CR in
this patient, it did reduce peripheral blast counts and pro-
vided 6 months of disease control, allowing time to poten-
tially coordinate a stem cell transplant. This response is
consistent with pre-clinical models of RAS-activated AML
in which trametinib inhibited leukemic proliferation but
did not eradicate disease [15].
Disease control by trametinib also highlighted another
interesting aspect of this case. Progressive clonal evolu-
tion was identified both through increasing cytogenetic
complexity with development of at least four subclones.
Targeted massively parallel sequencing analysis also
demonstrated clonal evolution, with the development of
two point mutations in WT1. We hypothesize that the
p53 mutation contributed to the complex clonal evolu-
tion and disease progression, as loss of p53 function is
known to impair DNA repair and genomic stability [16].
The use of next-generation sequencing to identify
potentially targetable mutations is an emerging area of
interest, particularly for rare or refractory malignancies.
A small clinical series using sunitinib to treat refractory
GCT identified amplification of the RET gene in one
exceptional responder [17]. Other potential approaches
to treating rare malignancies include basket trials, in
which patients with a specified mutations are treated
with targeted therapy irrespective of their underlying
malignancy, or umbrella trials, in which patients with a
defined cancers type are subclassified by genotype, and
then treated based on their molecular classification [18].
Our approach blends genotype with functional in vitro
drug screen as an additional predictor of targeted drug
response to identify potential therapeutic targets.
Conclusions
In conclusion, we report a case of metasynchronous medi-
astinal GCT and AML in a young male patient with identi-
cal TP53 and NRAS mutations in both malignancies. In
vitro functional assays were used to confirm the importance
of the NRAS mutation to leukemic blast proliferation and
the ability of trametinib to inhibit growth. Trametinib ther-
apy led to sustained disease control in vivo over 6 months
following failure of conventional cytotoxic chemotherapy.
This case highlights the power of in vitro functional assays
to identify novel targeted agents to treat rare and aggressive
malignancies and supports the exploratory use of small
molecule kinase inhibitors in the treatment of AML, par-
ticularly in rare presentations of AML where therapeutic
options are limited and outcomes are poor.
Consents
Written informed consent was obtained from the patient to
participate in a trial which would allow collection and se-
quencing of his leukemic blasts for sequencing and testing
against a panel of small molecule inhibitors. In addition, he
consented to sequencing of his normal tissue and his germ
cell tumor. The patient is deceased and had no next of kin
or legal guardian, so consent for publication of this case
report and any accompanying images was not obtained. This
lack of support contributed to his inability to proceed to allo-
geneic stem cell transplant.
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